Irinotecan combined with short-term radiotherapy for treating locally advanced middle-low rectal cancer
10.13929/j.issn.1672-8475.2024.09.004
- VernacularTitle:伊立替康联合短程放射治疗用于中低位局部晚期直肠癌
- Author:
Yifei LI
1
;
Kai TAO
Author Information
1. 山西省肿瘤医院/中国医学科学院肿瘤医院山西分院/山西医科大学附属肿瘤医院放射治疗科,山西 太原 030013
- Keywords:
rectal neoplasms;
adenocarcinoma;
neoadjuvant therapy
- From:
Chinese Journal of Interventional Imaging and Therapy
2024;21(9):527-531
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy of irinotecan combined with short-term radiotherapy for treating locally advanced middle-low rectal cancer.Methods Totally 140 rectal adenocarcinoma patients of stage Ⅱ—Ⅲ who underwent total mesorectal excision(TME)and FOLFOX6 adjuvant chemotherapy were retrospectively enrolled.The patients were divided into irinotecan+short-term radiotherapy group(group A,n=67,total radiation dose of 25.0 Gy)and long-term chemoradiotherapy group(group B,n=73,total radiation dose of 50.4 Gy)according to the neoadjuvant chemoradiotherapy(NCRT)plan.The short-term efficacy,incidence of toxic and side effects after radiotherapy,as well as long-term postoperative efficacy were compared between groups.Results Sixty-one patients(61/67,91.04%)in group A and 65 patients(65/73,89.04%)in group B successfully completed NCRT+TME+FOLFOX6 adjuvant chemotherapy.The proportion of complete response(CR)12 weeks after radiotherapy and disease free survival rate(DFS)3 years after TMF in group A were both higher than those in group B(both P＜0.05).No significant difference of proportion of progressive disease,stable disease and partial response 12 weeks after radiotherapy,the incidence of toxic and side effects 12 weeks after radiotherapy,overall survival,recurrence free survival nor distant metastasis 5 years after TME was found between groups(all P＞0.05).Conclusion Irinotecan combined with short-term radiotherapy was effective and relatively safe for treating locally advanced middle-low rectal cancer.
